离体高频超声与粗针活检改善膀胱癌临床分期初探
这项前瞻性研究评估离体高频超声(HF-US)和超声引导粗针活检(CNB)能否准确检出肌层浸润性膀胱癌(MIBC)。48例接受HF-US、32例接受CNB,HF-US检出MIBC准确率89.6%,CNB准确率90.6%,两者联合准确率92.0%、灵敏度100%、阴性预测值100%,均高于常规临床分期(55.6%)。
要点
- 离体HF-US检出MIBC准确率89.6%,阴性预测值96.0%。
- 离体CNB准确率90.6%,特异度和阳性预测值均为100%。
- 两法联合准确率92.0%、灵敏度100%、阴性预测值100%。
核心结论
- 离体HF-US和超声引导CNB能高准确度判定MIBC,阴性预测值尤其突出。
研究设计与样本
- 前瞻性研究纳入54例因尿路上皮癌行根治性膀胱切除术(RC)的患者,48例接受离体HF-US,32例接受CNB。
- HF-US图像与活检标本分别由盲法泌尿生殖放射科医生和病理科医生判读,并与RC病理分期(pT)比较。
- 共同主要终点为HF-US和CNB识别MIBC的准确率。
主要发现
- HF-US检出MIBC准确率89.6%,灵敏度95.0%,特异度85.7%,阴性预测值96.0%。
- CNB准确率90.6%,特异度和阳性预测值均为100%。
- 同时接受两种检查的25例中,联合方法准确率92.0%、灵敏度100%、阴性预测值100%。
- 常规临床分期准确率显著更低(55.6%),新辅助全身治疗后为40.0%。
- 接受新辅助全身或膀胱内治疗的患者中,HF-US和CNB诊断性能仍保持较高。
临床怎么用
- 结果支持进一步研究在体腔内超声和CNB分期,以改善膀胱癌风险分层和治疗选择。
局限性
- 本研究为离体设置,样本量有限(HF-US 48例、CNB 32例、联合25例)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate whether high-frequency ultrasound (HF-US) and ultrasound-guided core needle biopsy (CNB) can accurately detect muscle-invasive bladder cancer (MIBC) in an ex-vivo setting. METHODS: In this prospective study, patients undergoing radical cystectomy (RC) for urothelial carcinoma underwent ex-vivo HF-US of the extirpated bladder to assess depth of tumor invasion (ultrasound stage, usT). In a subset, HF-US guided CNB of the opened bladder targeted the deepest region of tumor invasion (cnbT). Ultrasound images and biopsy specimens were interpreted by a blinded GU-radiologist and pathologist, respectively and were compared with RC pathologic stage (pT). Co-primary endpoints were accuracy of HF-US and CNB in identifying MIBC. RESULTS: Among 54 patients, 48 underwent HF-US and 32 underwent CNB. HF-US demonstrated an accuracy of 89.6% for detecting MIBC, with sensitivity 95.0%, specificity 85.7%, and negative predictive value (NPV) 96.0%. CNB accuracy was 90.6%, with specificity and positive predictive value of 100%. In patients undergoing both modalities (n=25), a combined approach demonstrated 92.0% accuracy, 100% sensitivity, and 100% NPV. Conventional clinical staging had significantly lower accuracy (55.6%), particularly following neoadjuvant systemic therapy (40.0%). Diagnostic performance of HF-US and CNB remained high in patients treated with neoadjuvant systemic or intravesical therapy. CONCLUSION: HF-US and ultrasound-guided CNB were highly accurate in determining MIBC and specifically demonstrated excellent NPV. These findings support further investigation of in-vivo endoscopic ultrasound and CNB staging to improve risk stratification and treatment selection in bladder cancer.
引用
- Roberson DS, Wang MK, McLeay Ii MT, et al. A Pilot Study of Ex-vivo High Frequency Ultrasound and Core Needle Biopsy to Improve Clinical Tumor Staging of Cancer of the Bladder. Urology. 2026. PMID: 42336158. doi:10.1016/j.urology.2026.06.031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。